Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Drugs 74(17):2097103
The MHRA and EMA do not list blood clots as a recognised adverse effect of GLP-1 agonists
Research from ACR Convergence 2025 highlighted GLP-1 receptor agonists as showing particular promise in psoriatic arthritis management, where the dual burden of skin and joint disease creates challenges for conventional therapies
doi:10.1016/S0014-2999(96)00795-9 42
Beyond the GLP-1 receptor, it also targets the GIP (glucose-dependent insulinotropic polypeptide) receptor
These trials demonstrated its efficacy and safety in Type 2 diabetes with or without other anti-diabetic agents [42, 44,45,46,47]
US$ 22.38
US$ 24.52
US$ 27.91
US$ 28.52
US$ 28.27
